体外研究 (In Vitro) |
Nigakinone (10 μM; 24 h) 在 HEK293T 细胞中功能性激活 hFXR,以 hFXR 依赖的方式显著提升 BSEP 启动子活性。 Nigakinone (0.2-5 μM; 24 h) 可通过激活 FXR 缓解 Lithocholic acid (LCA) (MS-A96711) 诱导的 CT26 细胞炎症反应及紧密连接损伤,而该作用在 FXR 沉默细胞中被消除。 Nigakinone (0.2-5 μM) 可显著上调低表达 FXR 的 HCT116 结肠癌细胞中 FXR 蛋白的表达。 Nigakinone (0.2-5 μM) 可显著上调低表达 FXR 的 Caco-2 结直肠癌细胞中 FXR 蛋白的表达。 Nigakinone 在 FXR 低表达的 HCT116 结直肠癌细胞中作为 FXR 激动剂,可诱导 FXR 下游靶基因 FGF19 和 SHP 呈浓度依赖性上调。 Nigakinone 可在高表达 FXR 的 HT-29 结肠癌细胞中作为 FXR 激动剂,显著上调 FXR 下游靶基因 FGF19 和 SHP。 Nigakinone (0.2-5 μM; 48 h) 与 Irinotecan 协同抑制低 FXR 表达的 HCT116、Caco-2 及 HT-29 siFXR 结直肠癌细胞的活力。 Nigakinone (1 μM; 24 h, 48 h) 与 Irinotecan 协同抑制低 FXR 表达的 HCT116、Caco-2 以及 HT-29 siFXR 结直肠癌细胞的迁移。 Nigakinone (1 μM; 48 h) 可与 Irinotecan 协同抑制低 FXR 表达的 HCT116 和 Caco-2 结直肠癌细胞的克隆形成活性。
Cell Viability Assay
| Cell Line: |
FXR-low HCT116, Caco-2, and HT-29 siFXR (FXR-knockdown) colorectal cancer cells |
| Concentration: |
0.2, 1, 5 μM nigakinone; 5, 10, 20 μM irinotecan |
| Incubation Time: |
48 h |
| Result: |
Exhibited significant synergistic inhibition of cell viability across all tested cell lines. Showed Q values predominantly exceeding 1.15 and CI values below 1 across different concentration combinations. Achieved synergy at lower concentrations than silibinin, a comparable dual FXR inducer/agonist. |
Cell Migration Assay
| Cell Line: |
FXR-low HCT116, Caco-2, and HT-29 siFXR colorectal cancer cells |
| Concentration: |
1 μM nigakinone; 10 μM irinotecan |
| Incubation Time: |
24 h, 48 h |
| Result: |
Exhibited significant synergistic inhibition of cell migration at both 24 h and 48 h across all tested cell lines. Showed Q values ranging from 1.15 to 1.61 and CI values ranging from 0.29 to 0.57. |
|
体内研究 (In Vivo) |
Nigakinone (25-100 mg/kg;口服;每日;连续 9 天) 可通过激活 FXR 来减轻炎症、保护肠黏膜屏障并调控胆汁酸稳态,从而缓解 DSS (MS-A45736) 诱导的 SD 大鼠溃疡性结肠炎。 Nigakinone (60 mg/kg;口服;每日一次;连续 9 天) 通过抑制 NLRP3 介导的炎症反应、保护肠黏膜屏障,并经激活 FXR 调控胆汁酸肠肝循环,缓解 DSS 诱导的野生型 C57BL/6 小鼠溃疡性结肠炎。 Nigakinone (60 mg/kg;口服;每日一次;连续 9 天) 无法缓解 DSS 诱导的 FXR 敲除型 C57BL/6N 小鼠的溃疡性结肠炎,证实 FXR 是 nigakinone 发挥结肠炎治疗作用的必需条件。 Nigakinone (35 mg/kg;腹腔注射;每日一次;连续 21 天) 可通过上调 FXR 单独抑制结直肠癌异种移植物的生长;当其与 Irinotecan 联用时,可发挥协同抗肿瘤活性,增强对细胞增殖的抑制并诱导细胞凋亡。
| Animal Model: |
Sprague-Dawley (SD) (male, 200-220 g, ulcerative colitis induced by 4% DSS ad libitum for 7 days) |
| Dosage: |
25 mg/kg; 50 mg/kg; 100 mg/kg |
| Administration: |
p.o.; daily; 9 days |
| Result: |
Significantly reduced body weight loss, lowered DAI scores, decreased myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) levels, and alleviated colon tissue damage including mucosal ulceration, crypt loss, and inflammatory infiltration. Significantly reduced colon tissue mRNA expression of NLRP3 and caspase-1, and protein expression of NLRP3, caspase-1, IL-1β, ASC-2, and pro-caspase-1 (100 mg/kg dose). Significantly increased colon tissue mRNA expression of tight junction proteins ZO-1, Claudin-1, and Occludin, and protected colonic microvilli and tight junctions (100 mg/kg dose). Significantly reduced total bile acid (TBA) pool size in serum, liver, ileum, and colon; decreased BA proportion in liver and colon while increasing BA proportion in serum and ileum; shifted BA profile to reduce primary BA and increase secondary BA (100 mg/kg dose). Significantly increased mRNA and protein expression of FXR in liver and ileum; increased liver mRNA expression of BSEP, ileum mRNA expression of FGF15, ASBT, and IBABP; and decreased liver protein expression of CYP7A1 and NTCP (100 mg/kg dose). Significantly increased colon tissue mRNA and protein expression of FXR. |
| Animal Model: |
C57BL/6 (WT) (male, 20-22 g, ulcerative colitis induced by 3.5% DSS ad libitum for 7 days) |
| Dosage: |
60 mg/kg |
| Administration: |
p.o.; daily; 9 days |
| Result: |
Significantly reduced body weight loss, lowered DAI scores, reversed colon length shortening, decreased serum levels of MPO, TNF-α, and IL-1β, and reduced colon histological scores and tissue damage. Significantly increased colon tissue mRNA and protein expression of FXR; reduced mRNA and protein expression of NLRP3, IL-1β, TNF-α, ASC-2, and pro-caspase-1; and increased mRNA and protein expression of tight junction proteins ZO-1 and Claudin-1. Significantly reduced total BA pool size, decreased BA proportion in liver and colon while increasing BA proportion in serum and ileum, increased liver protein expression of FXR, BSEP, SHP, and OSTβ, decreased liver protein expression of CYP7A1 and NTCP, and increased ileum protein expression of FXR, IBABP, and OSTβ. |
| Animal Model: |
C57BL/6N (FXR KO) (male, 20-22 g, ulcerative colitis induced by 3.5% DSS ad libitum for 7 days) |
| Dosage: |
60 mg/kg |
| Administration: |
p.o.; daily; 9 days |
| Result: |
Did not significantly reduce body weight loss, lower DAI scores, reverse colon length shortening, decrease serum levels of MPO, TNF-α, and IL-1β, or reduce colon histological scores and tissue damage. Did not significantly reduce colon tissue mRNA or protein expression of NLRP3, IL-1β, TNF-α, ASC-2, or pro-caspase-1, or increase mRNA or protein expression of tight junction proteins ZO-1 and Claudin-1. Did not significantly reduce total BA pool size, alter BA proportion distribution in serum, liver, ileum, or colon, or regulate liver or ileum protein expression of bile acid transporters and regulators. |
| Animal Model: |
BALB/c nude (5-week-old, male, SPF-grade, HCT116 cell-derived subcutaneous xenograft model) |
| Dosage: |
35 mg/kg (single agent); 35 mg/kg (in combination with irinotecan 40 mg/kg) |
| Administration: |
i.p.; daily; 21 days (single agent); i.p.; daily (nigakinone) + weekly (irinotecan); 21 days (combination) |
| Result: |
Reduced tumor weight relative to the control group. Significantly upregulated FXR protein expression in tumor tissues compared to the control and irinotecan-only groups. Decreased Ki67 expression compared to the control group. Increased cleaved caspase 3 expression compared to the control group. Produced a synergistic reduction in tumor volume relative to irinotecan alone when combined with irinotecan. Produced a synergistic reduction in tumor weight relative to irinotecan alone when combined with irinotecan. Further decreased Ki67 expression compared to irinotecan alone when combined with irinotecan. Further increased cleaved caspase 3 expression compared to irinotecan alone when combined with irinotecan. Maintained significant FXR upregulation in tumor tissues when combined with irinotecan. Showed no significant differences in organ indices (heart, liver, lung, spleen, kidneys, brain) or colon length between nigakinone-treated and control groups, indicating good tolerability. |
|